Ariad investors retreat on FDA probe of Iclusig
This article was originally published in Scrip
Executive Summary
After taking a beating earlier in the week, shares of Ariad Pharmaceuticals were pounded again on 11 October, tumbling as low as 22%, after US regulators said they had opened a probe into the increase in reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the company's oral leukemia drug Iclusig (ponatinib), a kinase inhibitor.